Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma
Astellas Pharma Inc. announced that China’s National Medical Products Administration (NMPA) has approved Vyloy (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally …